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tion	but	a	residual	risk	of	 ischemic	events	still	 remains.	Alterations	of	 lipoproteins,	
specially,	increase	in	small	dense	LDL	(sdLDL)	particles	are	related	to	this	risk.
Objective: To	 investigate	 the	 potential	 use	 of	 sdLDL	 cholesterol	 concentration	
(sdLDL-C)	isolated	by	an	easy	precipitation	method	and	to	assess	the	impact	of	a	set	
of	clinical	and	biochemical	variables	determined	by	NMR	on	sdLDL	concentration.
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1  | INTRODUC TION
Cardiovascular	diseases	(CVD)	are	the	leading	cause	of	mortality	in	
the occidental countries being subclinical atherosclerosis the trig-
gering factor for most of these events.1 Premature atherosclerotic 
disease commonly occurs in individuals with atherogenic dyslipid-
emia	who	share	a	phenotype	characterized	by	centripetal	obesity,	
insulin	resistance,	and	physical	inactivity.	In	addition,	they	also	have	
a	 lipid	profile	characterized	by	an	 increase	 in	triglycerides	(Tg)	and	
small	 dense	 lipoproteins	 (sdLDL)	 concentrations.	 Also,	 a	 decrease	
in	 concentration	 of	 high-density	 cholesterol	 (HDL)	 and	 normal	 to	
moderately	elevated	low-density	lipoprotein	cholesterol	(LDL-C)	are	
generally observed in these patients.2
Reducing the incidence of cardiovascular events requires the 
early	 detection	 of	 cardiovascular	 risk	 factors	 (CVRFs),	 such	 as	
LDL-C	 concentration,	 nowadays	 the	 most	 important	 therapeutic	
target.3	 However,	 it	 has	 been	 demonstrated	 that	 lowering	 LDL-C	
concentration is not enough to prevent all ischemic events even in 
patients	without	CVRFs.4	People	with	LDL-C	concentrations	lower	





tection,	 and	 treatment	 strategy	based	on	 lowering	LDL-C	concen-
tration would be not enough for preventing all premature ischemic 
events.	Nowadays,	in	some	American	scientific	societies	the	LDL-C	
therapeutic threshold value is simply being lowered.6	Nevertheless,	
the	 latest	data	suggest	 that	LDL-C,	by	 itself,	cannot	explain	all	as-
pects	of	atherosclerotic	disease,7,8	summarizing	that	LDL-C	is	not	a	
good predictor of cardiovascular events in all cases.9
The	number	of	particles,	 their	 size,	 and	cholesterol	 concentra-
tion in different subclasses of lipoproteins are three factors that 
could	 be	 useful	 to	 estimate	 the	 residual	 cardiovascular	 risk	 unex-
plained	 by	 LDL-C	 concentrations	 alone.8-10	 It	 is	 well	 known	 that	
sdLDL	particles	 are	more	atherogenic.	Due	 to	 their	 small	 size	 and	
high	density,	these	particles	can	easily	infiltrate	the	vascular	endo-





are not being easily implemented in the clinical routine.15 The princi-
pal	reason	is	that	quantifying	sdLDL	concentration	is	expensive	and	
time	consuming.	An	alternative	method	using	Magnesium	Heparin	




et al tested different combinations of polyanion and divalent cations 
and	compared	the	results	with	the	reference	method,	the	ultracen-
trifugation. They achieved to find the combination which showed 
the best correlation with results obtained by the ultracentrifugation. 
They	concluded	that	the	combination	of	150	U/mL	Heparin-Na	and	





number and diameter of lipoprotein particles from different sub-










Taking	 into	 account	 the	 literature,	 LDL-P	has	been	established	
as	 a	 predictor	 of	 cardiovascular	 events.	However,	 the	 relationship	
between	LDL-P,	LDL-Z,	and	LDL-C	is	still	unclear.
The aim of this study is to investigate the relationship between 
sdLDL-C	 obtained	 by	 precipitation	 and	 characteristics	 established	
by	NMR	in	order	to	know	whether	performing	the	sdLDL-C	concen-
tration measurement could be useful as a complementary tool in car-
diovascular	risk	assessment.






and	history	of	 familial	 hypercholesterolemia	 and	 chronic	 diseases,	
such	 as	 diabetes,	 cancer,	 heart	 failure,	 and	 arterial	 hypertension.	











The research protocol was approved by the ethics committees of 
both participating hospitals.
Each	 patient	 had	 their	 biochemical	 profiles	 assessed.	 This	 in-
cluded	plasma	concentrations	of	alanine	aminotransferase	(ALT),	as-
partate	 aminotransferase	 (AST),	 glutamate-pyruvate	 transaminase	
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(GPT),	 creatinine,	 c-reactive	 protein	 (CRP),	 albumin,	 transthyre-
tin,	 glucose,	 Free	 Fatty	 Acids	 (FFAs),	 polyunsaturated	 fatty	 acids	
(PUFAs),	 monounsaturated	 fatty	 acids	 (MUFAs),	 fibulin	 (Fib),	 vi-
tamin	A	 (Vit	A),	 and	vitamin	E	 (Vit	 E).	A	 complete	 lipid	profile	 for	
each patient was also attained including plasma concentrations of 
cholesterol,	 very	 low-density	 lipoprotein	 cholesterol	 (VLDL-C),	 in-
termediate-density	lipoprotein	cholesterol	(IDL-C),	triglycerides	(Tg),	
low-density	lipoprotein	cholesterol	(LDL-C),	high-density	lipoprotein	
cholesterol	 (HDL-C),	 apolipoprotein	 A	 (ApoA-I),	 apolipoprotein	 B	
(ApoB),	 apolipoprotein	E	 (ApoE),	 apolipoprotein	CIII	 (ApoCIII),	 and	
lipoprotein	A	(LPA).	In	addition,	atherogenic	indices	were	calculated	
using	 the	 following	 formula:	 IA	=	LDL-C/HDL-C.	 LDL-Z	and	LDL-P	
and	sdLDL-C	were	also	measured	(Table	1).
2.2 | Determining sdLDL-C
As	a	 first	 step,	 sdLDL	particles	were	 isolated.	This	was	carried	out	
using a previously reported precipitation method adapted for use 
in our laboratory to process samples containing elevated concen-
trations of triglycerides. This method has been validated comparing 
the	 results	 obtained	with	 the	 reference	method,	 the	 ultracentrifu-
gation.16,17 Interassay imprecision of the precipitation method was 
calculated	 measuring	 10	 aliquots	 of	 2	 samples,	 one	 of	 them	 with	
pathological	values	of	sdLDL-c	and	the	other	one	with	values	within	
the	 reference	 interval	 for	 sdLDL-c.	The	study	has	been	carried	out	
during	2	weeks,	 and	 the	aliquots	were	 stored	at	−80C°.	 Interassay	
imprecision	estimated	by	the	variation	coefficient	(CV	%)	was	9%,	2%.








1.044	 and	 1.063	 g/mL.	 Supernatant	 HDL-C	 and	 total	 cholesterol	
were	 measured	 using	 a	 Cobas	 8000	 modular	 analyzer	 (Roche® 
Diagnostics by homogeneous assays. The linearity range for cho-
lesterol	(Cholesterol	gen.2)	is	0.08-20.7	mmol/L	and	for	HDL	(HDL-
Cholesterol	plus	3rd	generation)	is	0.08-3.12	mmol/L.
Cholesterol	 concentration	 is	 determined	 enzymatically	 using	







sdLDL-C	was	 calculated	 by	 subtracting	 the	 HDL-C	 from	 the	 total	
cholesterol concentration.
TA B L E  1   Demographic variables and lipid and biochemical 
profile
Variable Units Average (range)
Age years 45.8	(19-75)
BMI kg/cm2 25.1	(19.3-30)
Systolic	pressure mm Hg 124	(100-140)
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2.3 | NMR characterization of LDL particles
The	NMR	analyses	were	 carried	out	with	 the	Vantera®	 analyzer	
(LipoScience.	Inc).	This	equipment	is	approved	for	in	vitro	diagno-
ses	by	the	US	Food	and	Drug	Administration	(FDA).	This	technique	
was	 used	 to	 determine	 the	 LDL	diameters	 and	 estimate	 particle	
concentrations	(LDL-Z	and	LDL-P).	NMR	spectra	were	acquired	by	
400	MHz	1H	NMR	spectrometers	included	in	the	Vantera	Clinical	
Analyzer.	 The	 methyl	 signal	 envelope	 appearing	 between	 0.718	
and	 0.914	 ppm	 was	 analyzed	 using	 the	 LipoProfile-3	 algorithm.	




2.4.1 | Validation of precipitation technique to 
measure sdLDL-C
First	of	all,	a	correlation	study	was	carried	out	in	order	to	assess	the	
association	 between	 LDL-Z,	 LDL-p,	 and	 sdLDL-C	 by	 precipitation.	
The	NMR	 lipid	 profile	 data	 are	 use	 as	 the	 gold	 standard.	Outliers	
were	 identified	 using	 the	 Bland-Altman	 concordance	 analysis	 of	
paired	 data.	 The	 association	 of	 sdLDL-C	 with	 LDL-Z	 and	 LDL-P	
was determined by calculating the Pearson correlation coefficient 
(rxy)	with	a	confidence	interval	of	95%	[95%	CI]	as	well	as	levels	of	
significance.
2.4.2 | Assessing the impact of a set of clinical and 
biochemical variables on sdLDL concentration
To	 study	 the	 relation	 between	 LDL-Z	 and	 sdLDL-C,	 a	multivariate	
regression analysis adjusted for control variables was performed. 
Here,	 the	 dependent	 variable	 (Y)	was	 the	 sdLDL-C,	 and	 the	 inde-
pendent	variable	(X)	was	LDL-Z.
Those	 variables	 which	 contribute	 significantly	 to	 the	 sdLDL-C	




Those variables with a ρ	 >	 0.5	were	 discarded.	 A	multivariate	 re-
gression model was constructed using the selected variables. The 
adjusted	coefficient	of	determination	(adjusted	R2)	was	calculated	to	
determine	the	proportion	of	variation	in	sdLDL-C	concentration	that	
could	be	explained	by	the	adjusted	model.	B	and	β coefficients were 
used to assess the contribution of each variable to the multivariate 
regression	model.	A	higher	β coefficient was indicative of a greater 
contribution.








3.2 | Validation of precipitation technique to 
measure sdLDL-C
Only three outliers were discarded. The correlation study showed 
that	 there	 was	 a	 direct	 linear	 association	 between	 sdLDL-C	 and	





ciations were statistically significant.
3.3 | Impact of a set of clinical and biochemical 
variables on sdLDL concentration











The multivariate regression model was found to be significant 
(P	=	8.77	×	10−12; R2	=	0.568).	The	model	explains	56.8%	of	sdLDL-C	
variation. Regression coefficients were calculated for each variable 












tion with all variables collected was investigated.
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In	Tables	1	and	2,	some	characteristic	of	population	studied	are	
shown.	 In	 table	 1,	means	 and	 ranges	 of	 each	 variable	 included	 in	
VITAGE	study	can	be	seen.	Means	and	ranges	from	each	variable	are	
representative of general population.
With	these	data,	the	principal	aim	of	this	study	was	to	investigate	
the relationship between all these characteristics and the concentra-
tion	of	sdLDL-C	obtained	by	precipitation.
Firstly,	 a	 correlation	 study	was	 carried	 out	 as	 a	 tool	 to	 assess	
the	validity	of	the	precipitation	method	As	shown	in	Figures	1	and	
2,	there	was	a	direct	linear	association	between	sdLDL-C	and	LDL-P	
(rxy	 =	 0.687	 [0.555-0.785];	P = 2.1 × 10
−7).	 Besides,	 there	was	 an	
inverse	 association	 between	 sdLDL-C	 and	 LDL-Z	 (rxy	 =	 −0.603	
[−0.723-0.447];	P	=	1.6	×	10−12).	Both	were	statistically	significant	
associations.
The	 strong	positive	 association	between	 sdLDL-C	 and	 LDL-P	
proves that the cholesterol isolated by the precipitation method 
represents	 a	 great	 part	 of	 the	 cholesterol	 contained	 in	 sdLDL	
particles	 as	 determined	 by	NMR.	 Therefore,	 it	 could	 be	 that	 by	
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measuring	sdLDL-C,	LDL-P	can	be	estimated.	On	the	other	hand,	
the	 negative	 association	 between	 in	 sdLDL-C	 concentration	 and	






whether it is possible to estimate the presence of particles of small 
size	and	its	number	by	measuring	sdLDL-C.
According	 to	 recent	 articles,	 it	 seems	 that	 the	 presence	 of	
an	elevated	number	of	sdLDL	particles	is	a	clear	risk.	In	fact,	the	
Hortega-Liposcale	 Follow-up	 study	 23 found an association be-
tween	 the	 presence	 of	 lipoproteins	with	 small	 and	medium	 size	
and	the	increased	cardiovascular	risk,	especially	of	coronary	heart	
disease.
This is particularly important due to the fact that discordance 
between	LDL-C	and	LDL-P	has	been	described	 in	some	cases.20,21 
The discordance is due to the fact that cholesterol concentration 
in	these	particles	varies	depending	on	the	size	of	the	different	LDL	
subclasses.20-22	Especially	relevant	is	the	MESA	study.22 This study 
has	demonstrated	the	discordance	between	LDL-C	and	LDL-P	and	its	









eficial	 in	patients	with	 intermediate	CHD	risk,	 since	 they	could	be	
benefit from intensive treatments.28
























VLDL-C	(mmol/L) 688.12 1.02 × 10−9
Apo	A	(mg/dL) −5.036 0.002





















TA B L E  3   Regression coefficients for the variables included in 
the multivariate model
Variable B [95% CI] β P
Age	(y) 0.169	[−2.627	a	2.966] 0.011 .904
BMI	(kg/cm2) 0.016	[0.032	a	0.114] 0.175 .048
ALT	(µkat/L) 78.172	[−95.288	a	251.631] 0.068 .372
Vit	E	(µmol/L) −8.780	[−20.717	a	3.158] -0.230 .147
Tg	(mmol/L) 0.182	[0.391	a	0.325] 0.352 .013
HDL-C	(mmol/L) -10.388	[−248.315	a	227.539] -0.013 .931
IDL-C	(mmol/L) 245.684	[−769.679	a	278.312] 0.080 .353
Apo	B	(mg/dL) 0.071	[0.025	a	0.116] 0.415 .003
Apo	E	(mg/dL) 3.997	[−70.137	a	62.142] −0.011 .904
Apo	CIII	(mg/dL) 10.638	[−27.980	a	6.702] 0.132 .225
FFAs	(ng/mL) 0.001	[−0.004	a	0.061] 0.264 .084
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On	 account	 of	 these	 studies,	 LDL-C	 concentration	 is	 not	
enough	 to	 estimate	 the	 cardiovascular	 risk	 in	 patients	 in	 which	
LDL-C	 goals	 are	 achieved	 but	 elevated	 concentration	 of	 sdLDL	
particles	 is	 found.	 Keeping	 in	 mind	 this	 fact,	 it	 would	 be	 really	
interesting	 to	 know	 this	 information	 through	 a	 simple,	 fast,	 and	
inexpensive	method.	 In	a	recent	study,	 it	was	demonstrated	that	
in	patients	with	elevated	LDL-P	the	risk	of	a	CHD	event	increased,	
and	 patients	 undergoing	 LDL-P	measurements	 were	more	 likely	
to	 receive	 more	 aggressive	 lipid-lowering	 therapy	 and	 had	 a	
lower	 cardiovascular	 risk	 than	 a	 cohort	 in	which	 just	 LDL-C	was	
measured.28,29
Considering	the	results	 from	this	 first	study,	a	regression	anal-
ysis was performed. The main objective of this second part is to 
assess the impact of a set of clinical and biochemical variables on 







The	 final	multivariate	model	 is	 summarized	 in	 Table	 3.	 It	 ex-
plains	a	57%	of	sdLDL-C	variation.	The	major	contributors	 in	the	
model	are	ApoB	and	LDL-Z.	This	is	a	coherent	result	because	sdLDL	
particles	 are	 formed	by	cholesterol	 and	a	 single	ApoB	molecule.	
However,	LDL-C	was	not	finally	included	in	the	last	model	due	to	
its	 collinearity	 with	 apoB	 and	 minor	 significance.	 Extrapolating	
to	clinical	practice,	these	results	agree	with	literature,	since	they	
imply	 that	 there	 are	 individuals	with	 a	 normal	 LDL-C	and	 a	high	
sdLDL-C	and	vice	versa.20 The discordance phenomenon could be 
present	 in	people	with	 low	LDL-C	concentration,	even	 in	people	
who	achieve	LDL-C	goals.20,21
Regarding	 the	 relation	 between	 sdLDL-C	 concentration	 varia-
tion	and	LDL-Z,	we	 found	 that	an	 increase	 in	 the	diameter	of	LDL	
particles	implies	a	decrease	in	sdLDL-C	concentration.	Importantly,	
taking	 into	 account	 the	 multivariate	 regression,	 an	 increment	 of	
1	nm	in	LDL	size	leads	to	a	126	nmol/L	reduction	in	sdLDL-C	con-
centration.	As	a	consequence,	smaller	LDL	particles	contain	a	higher	
concentration	 of	 cholesterol.	Due	 to	 its	 composition,	 smaller	 LDL	
particles would support the formation and progression of the ath-
eroma plaques in higher degree than larger ones. Considering the 
relationship	between	sdLDL	particles	and	the	development	of	ath-
erosclerosis,	sdLDL-C	should	be	thoroughly	investigated	as	a	novel	
predictor	 of	 premature	 ischemic	 events.	 Therefore,	when	NMR	 is	
not	available,	measuring	sdLDL-C	concentration	could	be	a	reliable	
tool	for	diagnosis	risk	stratification	instead	of	LDL-C	measurement.	
Implementing this method in clinical laboratories is easy since it 











more	 that	 it	 does	LDL-C;	 reviewing	 the	most	 relevant	 articles,	we	
could	deduce	that	the	LDL-C	reducing	therapies	should	not	be	the	
only therapeutic strategy for preventing atherothrombosis events. 
Other	factors	should	be	considered,	such	as	Tg	concentration,	which	
implies	sdLDL	particles	formation.
Only significant variables from the univariate analyses were used 
to construct the multivariate model.
Vitamin	E	concentration	 is	 relevant	even	though	 it	was	not	 in-

















be a good strategy to carry out.
5  | CONCLUSION
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